Moxonidine for Postural Orthostatic Tachycardia Syndrome (POTS)
Trial Summary
Will I have to stop taking my current medications?
The trial requires participants to stop taking medications that affect autonomic function, blood pressure, or blood volume. If you are on such medications, you will need to withdraw from them to participate.
Is moxonidine safe for human use?
Moxonidine has been studied for its safety in treating high blood pressure, with common side effects including dry mouth, sleepiness, headache, and dizziness. Serious side effects are rare, and it does not worsen conditions like diabetes or interact negatively with certain medications. Overall, it has a good safety profile for managing mild-to-moderate hypertension.12345
How is the drug Moxonidine unique in treating POTS?
What is the purpose of this trial?
This trial tests Moxonidine, a medication that calms overactive nerves controlling blood pressure and heart rate, on patients with POTS who have high nerve activity. The goal is to see if it can lower heart rate and improve symptoms when standing. Moxonidine is designed to reduce blood pressure with fewer side effects compared to older medications.
Research Team
André Diedrich, MD
Principal Investigator
Vanderbilt University Medical Center
Eligibility Criteria
This trial is for men and women aged 18-55 with Postural Orthostatic Tachycardia Syndrome (POTS) characterized by a rapid heartbeat upon standing. Participants must have high resting sympathetic nerve activity, not be pregnant or severely overweight, and cannot be taking certain medications that affect autonomic function.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single oral dose of moxonidine or placebo to assess the effects on orthostatic symptoms and hemodynamics
Observation
Participants are monitored for changes in heart rate and orthostatic symptom burden after administration
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Moxonidine
- Placebo
Moxonidine is already approved in European Union, Canada, China, Switzerland, United Kingdom for the following indications:
- Hypertension
- Hypertension
- Hypertension
- Hypertension
- Hypertension
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vanderbilt University Medical Center
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator